PONTE VEDRA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), announces it will highlight new product innovations at the 2022 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Quebec City, Canada from September 14-17.1

Several technologies will be highlighted at Treace’s booth (No. 301) at the AOFAS conference, including:

Lapiplasty® Micro-Incision™ System: The Lapiplasty® Micro-Incision™ System is a set of advanced instrumentation specifically developed to reduce the incision size required to perform the Lapiplasty® 3D Bunion Correction™ procedure. The advanced instrument set, including the Lapiplasty® Micro-Incision™ 3-n-1™ Guide and other specialized surgical instruments, allows the deformity correction and joint preparation steps of the patented Lapiplasty® Procedure to be performed through 2cm or less incisions. The Lapiplasty® Micro-Incision™ instrumentation is currently in limited clinical access.

SpeedPlate™ Rapid Compression Implants: The SpeedPlate™ implant system represents a new platform of Lapiplasty® fixation technology, providing foot and ankle surgeons with additional fixation options for Lapiplasty® and Adductoplasty™ procedures. SpeedPlate™ implants are designed for rapid fixation application while also providing dynamic compression of the joint surfaces. This new fixation platform is compatible with the Lapiplasty® Micro-Incision™ surgical approach. The patent-pending SpeedPlate™ System has been submitted for FDA 510(k) review and is not yet available for sale in the U.S.

New Lapiplasty® Innovations:   Recently commercialized innovations will also be featured at Treace’s booth and in hands-on training workshops, including the Lapiplasty® S4A Anatomic Plating Kit, the Lapiplasty® 3-n-1™ Guide, and the SpeedRelease™ and TriTome™ Tissue Release Instruments. These new technologies are available in full commercial release.

John T. Treace, CEO, Founder and Board Member of Treace, said “As the industry’s only company solely focused on advancing the standard of care in the surgical correction of bunion and related midfoot deformities, we are excited to feature our latest R&D innovations to surgeons attending the 2022 AOFAS conference. These new technologies demonstrate Treace’s commitment to rapid innovation with a focus on continually iterating the Lapiplasty® System with options for reduced incision size and increased procedural efficiency while maintaining the clinical outcomes associated with the Lapiplasty® Procedure.”

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

The American Orthopaedic Foot & Ankle Society® (AOFAS) mobilizes its global community of foot and ankle orthopaedic specialists to improve patient care through education, research, and advocacy. The AOFAS Annual Meeting is the premier event for foot and ankle education, offering presentations from renowned speakers, special interest forums, and the latest products and technology.

Treace products will be presented in Canada for demonstration purposes only. They are not licensed in accordance with Canadian regulations.

Contacts: Treace Medical Concepts, Inc. Mark L. Hair Chief Financial Officer mhair@treace.net (904) 373-5940

Investors: Gilmartin Group Lynn Lewis or Vivian Cervantes IR@treace.net

A labor shortage at a pharmaceutical company along with increased demand left Adderall on back-order at many pharmacies across the country.

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.

How do you fix a forgetful memory? Neurologist shares brain exercises to keep memory sharp, including reading fiction, cooking from recipes and playing games.

A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.

Getting rest days in between workouts is important for recovery

The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.

Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.

A device "unexpectedly detonated" on Thursday during the FBI Philadelphia field office's explosives training, leaving five law enforcement officers injured, officials said.

Here are a few complete protein combinations that aren’t beans and rice, plus the benefits of getting all the essential amino acids.

Former White House press secretary Sarah Sanders, who is running for governor in Arkansas, underwent surgery Friday for thyroid cancer. Sanders announced she underwent the surgery after a biopsy earlier this month revealed that she had thyroid cancer. Sanders was recovering at an Arkansas hospital on Friday, her campaign said.

Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.

And find out the benefits of adding weightlifting to your workout routine.

Robert Burns, who is running for Congress in New Hampshire, said a group of people would determine if the "life of the mother" is truly at risk.

Abortion ban legislation from Sen. Lindsey Graham adds to political challenge for Republicans.

By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Moving lead assets and earlier stage candidates forward … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, provided an update in a letter to shareholders this week. With a broad pipeline of

Workers and employers stand to save on health-insurance premiums in the coming years as Medicare drug-pricing reforms recently passed by Congress spill over into the commercial market, and states piggybacking on the federal rules may amplify the impact, health policy experts say. Although the Inflation Reduction Act’s drug-pricing provisions focus on the federal health program for seniors, including requiring that the federal government negotiate prices for certain Medicare-covered drugs, a new analysis published since the law’s passage last month points to potential benefits for people in employer-sponsored health plans. One of the law’s provisions, requiring pharmaceutical companies to pay rebates to Medicare when drug prices rise faster than inflation, translates into about $31.5 billion in employer and employee premium and cost-sharing savings over the next nine years, according to an estimate from nonprofit research organization West Health Policy Center.

Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete. On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published https://www.bmj.com/content/370/bmj.m3379 in the British Medical Journal. GSK and partner Vir Biotechnology's sotrovimab - which has generated billions in sales and became one of the British drugmaker's top sellers last year - was pulled off the U.S. market by the U.S. Food and Drug Administration (FDA) in April.

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has backed using AstraZeneca Plc's (NASDAQ: AZN) COVID-19 drug treatment. AstraZeneca said the EMA had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and are at increased risk of worsening their disease. The antibody cocktail was previously only approved as a preventative treatment for people with compromised immune systems who see little or n